Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Update

Health Catalyst, Inc. (NASDAQ:HCAT) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 2,340,000 shares, a growth of 7.3% from the August 31st total of 2,180,000 shares. Based on an average daily trading volume, of 547,200 shares, the days-to-cover ratio is presently 4.3 days.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, September 20th. Evercore ISI lowered their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Stephens lowered their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Finally, Piper Sandler reduced their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.42.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The disclosure for this sale can be found here. Insiders sold 35,361 shares of company stock valued at $248,033 over the last ninety days. 2.70% of the stock is owned by insiders.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC increased its position in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the last quarter. Millennium Management LLC grew its stake in shares of Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA increased its holdings in Health Catalyst by 14.7% during the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after buying an additional 305,079 shares during the last quarter. Daventry Group LP raised its position in Health Catalyst by 3.9% during the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after acquiring an additional 84,178 shares in the last quarter. Finally, Nepsis Inc. lifted its stake in Health Catalyst by 8.3% in the second quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock valued at $8,007,000 after acquiring an additional 95,686 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ HCAT traded down $0.17 during trading on Tuesday, hitting $7.97. The stock had a trading volume of 101,027 shares, compared to its average volume of 578,159. The company has a market capitalization of $470.51 million, a PE ratio of -4.40 and a beta of 1.31. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The company’s 50-day moving average price is $7.43 and its two-hundred day moving average price is $6.89.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The business had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. As a group, equities analysts anticipate that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.